NE-100

From Wikipedia, the free encyclopedia
Jump to: navigation, search
NE-100
NE-100.png
Systematic (IUPAC) name
4-methoxy-3-(2-phenylethoxy)-N,N-dipropylbenzeneethanamine
Clinical data
Legal status ?
Identifiers
CAS number 149860-29-7
ATC code ?
Chemical data
Formula C23H33NO2 
Mol. mass 355.51 g/mol

NE-100 or 4-methoxy-3-(2-phenylethoxy)-N,N-dipropylbenzeneethanamine is a selective sigma-1 receptor antagonist, with a reported binding affinity of Ki = 1.03 ± 0.01 nM, and more than 205 times selectivity over the sigma-2 receptor.[1][2]

NE-100 was one of the earliest selective sigma-1 receptor ligands reported and has been widely used as a pharmacological tool. The original, eight step synthesis of NE-100 was reported by Atsuro Nakazato and colleagues of Taisho Pharmaceutical Company in 1999.[3] More recently, Michael Kassiou and co-workers have reported a more expedient synthesis of NE-100 that proceeds in 56% unoptimized yield over 4 steps.[4]

References[edit]

  1. ^ Okuyama S, Nakazato A (1999). "NE-100: A novel sigma receptor antagonist". CNS Drug Rev. 2 (2): 226–237. 
  2. ^ Berardi F, Ferorelli S, Colabufo NA, Leopoldo M, Perrone R, Tortorella V (2001). "A multireceptorial binding reinvestigation on an extended class of sigma ligands: N-[omega-(indan-1-yl and tetralin-1-yl)alkyl] derivatives of 3,3-dimethylpiperidine reveal high affinities towards sigma1 and EBP sites". Bioorg. Med. Chem. 9 (5): 1325–35. doi:10.1016/s0968-0896(01)00011-6. 
  3. ^ Nakazato A, Ohta K, Sekiguchi Y, Okuyama S, Chaki S, Kawashima Y, Hatayama K (1999). "Design, Synthesis, Structure-Activity Relationships, and Biological Characterization of Novel Arylalkoxyphenylalkylamine s Ligands as Potential Antipsychotic Drugs". Journal of Medicinal Chemistry 42 (6): 1076–1087. doi:10.1021/jm980212v. 
  4. ^ Banister SD, Moussa IA, Jorgensen WT, Chua SW, Kassiou M (2011). "Molecular hybridization of 4-azahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodecane-3-ol with sigma (s) receptor ligands modulates off-target activity and subtype selectivity". Bioorg. Med. Chem. Lett. 21 (12): 3622–3626. doi:10.1016/j.bmcl.2011.04.098.